Remus Pharmaceuticals Limited — Updates, 14-08-2025: Press Release

Remus Pharmaceuticals reported strong Q1 FY25-26 financial results, with consolidated revenue reaching ₹ 193.44 Cr, marking a 46.02% year-on-year increase. Consolidated Profit Before Tax (PBT) rose 30.39% to ₹ 11.90 Cr. Growth was fueled by robust execution in new markets like Peru and El Salvador, alongside a diversified product portfolio focusing on Oncology, Biosimilars, and Peptides. The company secured a healthy consolidated order book of ₹ 170 Cr, ensuring future visibility. Strategic expansion into D2C and pharmacy networks is also accelerating market penetration, with the D2C channel poised for 100% revenue growth.